Epithelioid sarcoma: from SMARCB1 loss to therapeutic vulnerabilities

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epithelioid sarcoma (ES) is an ultra-rare soft tissue sarcoma with incidence <0.5 new cases/million/year.
• ES is defined by the loss of SMARCB1 expression, a key component of chromatin remodeling complexes.
• This loss results in transcriptional dysregulation and dependency on the Polycomb Repressive Complex 2 (PRC2) and its enzyme EZH2.

Purpose of the Study:

• To review the current therapeutic strategies for epithelioid sarcoma.
• To explore recent advances in the molecular characterization of ES.
• To identify potential novel treatment avenues for ES.

Main Methods:

• Literature review of current therapeutic landscape and molecular advances in epithelioid sarcoma.
• Analysis of molecular mechanisms underlying ES pathogenesis, including SMARCB1 loss and transcriptional changes.
• Evaluation of therapeutic targets and treatment outcomes, including EZH2 inhibitors.

Main Results:

• Loss of SMARCB1 in ES is primarily due to homozygous deletion on chromosome 22, leading to two distinct molecular subtypes.
• Transcriptional analysis identified potential therapeutic targets such as MYC, mTOR, and TEK.
• The EZH2 inhibitor tazemetostat was approved for advanced ES but faced challenges due to resistance mechanisms and secondary hematological malignancies.

Conclusions:

• Treatment options for epithelioid sarcoma remain limited, with a poor prognosis despite advances in understanding its biology.
• The rarity of ES hinders dedicated clinical trials and comprehensive molecular characterization.
• Further research is essential to develop more effective therapies for this rare cancer.